New Publication: Dupilumab Shows No Impact on Nasal Microbiome in N-ERD Patients
We’re pleased to announce the publication of our latest research in Frontiers in Immunology:
“Dupilumab treatment has no effect on the nasal microbiome in patients with NSAID-exacerbated respiratory disease: a longitudinal pilot study”
In this longitudinal pilot study, we investigated the effects of dupilumab—an IL-4Rα antagonist—on the nasal microbiome of patients with NSAID-exacerbated respiratory disease (N-ERD). Despite its known clinical benefits in treating type 2 inflammation, our findings reveal that dupilumab does not significantly alter the composition of the nasal microbiome over time.
These results add an important layer to our understanding of biologic treatments in airway disease, suggesting that clinical improvements seen with dupilumab occur independently of microbiome changes.
We’re excited to contribute to the growing body of research on N-ERD and precision therapies for airway inflammation. Stay connected with us for future updates and studies!
l
